Abstract
One of the major manifestations of the carcinoid syndrome is secretory diarrhea thought to be due to overproduction of 5-hydroxytryptamine (5-HT). Synthetic somatostatin analogues have proved to be clinically effective in controlling this diarrhea. We have established a continuous cell line from a human pancreatic carcinoid tumor that secretes 5-HT. We examined the ability of the somatostatin analogue, SMS 201-995, to inhibit 5-HT release in vitro. Tumor cells were exposed to SMS 201-995 (10-6 mol/L), pentagastrin (10-9 mol/L), acetylcholine (10-5 mol/L), and isoproterenol (10-5 mol/L) alone and in combination; 5-HT release was assayed with high pressure liquid chromatography. We found that pentagastrin (6.43 ± 0.64 ng/ml), isoproterenol (20.24 ± 2.17 ng/ml), and acetylcholine (12.39 ± 1.10 ng/ml) each stimulated release of 5-HT compared to control values (4.38 ± 0.42 ng/ml). SMS 201-995 significantly reduced release of 5-HT in response to isoproterenol and acetylcholine but did not inhibit the effect of pentagastin. These data suggest that different agents do not act through the same pathway to stimulate 5-HT release from human pancreatic carcinoid cells.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1131-1135 |
| Number of pages | 5 |
| Journal | Surgery |
| Volume | 108 |
| Issue number | 6 |
| State | Published - 1990 |
Fingerprint
ASJC Scopus subject areas
- Surgery
Cite this
The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor. / Lawrence, J. P.; Ishizuka, J.; Haber, B.; Townsend, Courtney; Thompson, J. C.
In: Surgery, Vol. 108, No. 6, 1990, p. 1131-1135.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - The effect of somatostatin on 5-hydroxytryptamine release from a carcinoid tumor
AU - Lawrence, J. P.
AU - Ishizuka, J.
AU - Haber, B.
AU - Townsend, Courtney
AU - Thompson, J. C.
PY - 1990
Y1 - 1990
N2 - One of the major manifestations of the carcinoid syndrome is secretory diarrhea thought to be due to overproduction of 5-hydroxytryptamine (5-HT). Synthetic somatostatin analogues have proved to be clinically effective in controlling this diarrhea. We have established a continuous cell line from a human pancreatic carcinoid tumor that secretes 5-HT. We examined the ability of the somatostatin analogue, SMS 201-995, to inhibit 5-HT release in vitro. Tumor cells were exposed to SMS 201-995 (10-6 mol/L), pentagastrin (10-9 mol/L), acetylcholine (10-5 mol/L), and isoproterenol (10-5 mol/L) alone and in combination; 5-HT release was assayed with high pressure liquid chromatography. We found that pentagastrin (6.43 ± 0.64 ng/ml), isoproterenol (20.24 ± 2.17 ng/ml), and acetylcholine (12.39 ± 1.10 ng/ml) each stimulated release of 5-HT compared to control values (4.38 ± 0.42 ng/ml). SMS 201-995 significantly reduced release of 5-HT in response to isoproterenol and acetylcholine but did not inhibit the effect of pentagastin. These data suggest that different agents do not act through the same pathway to stimulate 5-HT release from human pancreatic carcinoid cells.
AB - One of the major manifestations of the carcinoid syndrome is secretory diarrhea thought to be due to overproduction of 5-hydroxytryptamine (5-HT). Synthetic somatostatin analogues have proved to be clinically effective in controlling this diarrhea. We have established a continuous cell line from a human pancreatic carcinoid tumor that secretes 5-HT. We examined the ability of the somatostatin analogue, SMS 201-995, to inhibit 5-HT release in vitro. Tumor cells were exposed to SMS 201-995 (10-6 mol/L), pentagastrin (10-9 mol/L), acetylcholine (10-5 mol/L), and isoproterenol (10-5 mol/L) alone and in combination; 5-HT release was assayed with high pressure liquid chromatography. We found that pentagastrin (6.43 ± 0.64 ng/ml), isoproterenol (20.24 ± 2.17 ng/ml), and acetylcholine (12.39 ± 1.10 ng/ml) each stimulated release of 5-HT compared to control values (4.38 ± 0.42 ng/ml). SMS 201-995 significantly reduced release of 5-HT in response to isoproterenol and acetylcholine but did not inhibit the effect of pentagastin. These data suggest that different agents do not act through the same pathway to stimulate 5-HT release from human pancreatic carcinoid cells.
UR - http://www.scopus.com/inward/record.url?scp=0025667244&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025667244&partnerID=8YFLogxK
M3 - Article
VL - 108
SP - 1131
EP - 1135
JO - Surgery
JF - Surgery
SN - 0039-6060
IS - 6
ER -